Access
To read this story in full you will need to login or make a payment (see right).
Business
Nature 445, 355 (25 January 2007) | doi:10.1038/445355a; Published online 24 January 2007
Open Innovation Challenges
-
Novel Approaches to Protecting Maize from Insect Damage
The Seeker is looking for novel approaches to protecting maize from insect damage. This Challenge re...
-
Optimizing Sub-cellular Localization Tags
The Seeker is looking for methods to optimize sub-cellular localization tags for protein expression....
- More Challenges
- Powered by:
nature jobs
Head of Formulation R&D
- Syngene International Limited
- Bangalore 560 099 India
Postdoctoral Research in Functional Genomics
- Harvard School of Public Health, computer science, biology, bioinformatics,
- Boston, MA
In brief
European regulators are approving new drugs just as quickly, on average, as the US Food and Drug Administration (FDA), according to an assessment by the Tufts Center for the Study of Drug Development in Boston, Massachusetts. Tufts analysed the period from 2000 to 2005 and found that of 71 new drugs approved by both the European Medicines Agency and the FDA, the average times to approval were 15.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
